MAIA Biotechnology opened at $1.03, in line with its previous close of $1.03. In the last trading session, the stock traded between $1.00 and $1.06. It showed a downward intraday trend.
An investment of $100 made 5 years ago in MAIA Biotechnology is now worth
$ 22.76
Resulting in a loss of
$ 77.24 (77.24%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.02 (-1.46%)
Day High
$1.06
Day Low
$1.00
Day Open
$1.03
Prev Close
$1.03
Volume
2,59,253
1W Return
-10.18%
1M Return
-13.32%
3M Return
-26.71%
6M Return
-22.52%
1Y Return
-9.38%
Market Cap ($ Mn)
63
PE Ratio
-
PB Ratio
3.91
PEG Ratio
-
ROE
-753.00%
ROCE
-458.05%
EPS (TTM)
$-0.12
1 Week
-10.18%
1 Month
-13.32%
3 Months
-26.71%
6 Months
-22.52%
9 Months
-42.66%
MAIA Biotechnology files resale prospectus for 751,879 shares
MAIA Biotechnology filed a preliminary prospectus on September 25, 2026. The filing covers the resale of 751,879 common shares by PoC Capital, LLC. Shares were issued under a clinical trial funding agreement dated August 29, 2026. MAIA Biotechnology receives no proceeds from this share sale.
1mo agoMAIA Biotechnology expands Phase 3 THIO-104 trial into Spain and Portugal
MAIA Biotechnology secured regulatory approvals in Spain and Portugal for its Phase 3 THIO-104 trial. The company targets dosing 100 patients by year-end 2026 ahead of a 2027 interim analysis. Current enrollment stands at 65 patients across 28 European and 10 Taiwanese sites. Spain and Portugal account for an estimated 30,000 new NSCLC cases annually. Portugal reports the highest NSCLC proportion (82%) among five evaluated European populations.
1mo agoMAIA Biotechnology doses first US patient in Phase 2 lung cancer trial
MAIA Biotechnology doses first US patient in Phase 2 THIO-101 trial for NSCLC. US expansion funded by $2.3 million NIH grant with three active sites. Ateganosine showed 90.5% disease control rate in third-line studies. CEO Vlad Vitoc notes patient enrollment across four continents. Directors and officers hold 21.34% stake following recent insider purchases.
1mo agoMAIA Biotechnology files $150 million mixed shelf offering with SEC
MAIA Biotechnology files $150 million mixed shelf offering. Submission includes Form 3 insider ownership disclosures. Filing enables future issuance of various securities. No specific use of proceeds disclosed in current data.
2mo agoMAIA Biotechnology Q2 Results: EPS misses estimates
MAIA Biotechnology missed Q2 EPS estimates with a loss of $(0.13) per share versus the $(0.11) consensus. The miss represents an 18.18 percent deviation from expectations. However, the result is a 27.78 percent improvement compared to the $(0.18) loss in the same quarter last year.
3mo agoMAIA Biotechnology reports 90.5% disease control rate in NSCLC trial
MAIA Biotechnology reported a 90.5% disease control rate in its Phase 2 THIO-101 Part C trial for third-line non-small cell lung cancer, significantly outperforming standard chemotherapy rates. The data confirms previous efficacy signals in a more heavily pre-treated patient population.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in MAIA Biotechnology is now worth
$ 22.76
Resulting in a loss of
$ 77.24 (77.24%)
Note: Past profits do not guarantee future returns.
